SERPINE1 and metabolic dysfunction-associated steatohepatitis: Many different mechanisms may explain how NASH could contribute to vascular disease, for example, by increasing the production of pro-thrombotic factors by the liver, like plasminogen activator inhibitor-1 (PAI-1), which has been shown to have higher activity in patients with metabolic syndrome (Mertens and Van Gaal, 2006).